Is “Artificial” Intelligence an Option for your ADA?
In Case You Missed It: Better ADA Prediction!
Guilhem Richard, our CTO, recently presented our new ADA (anti-drug antibody) prediction model to the Antibody Society. The accuracy of the model improved from 63% (ADA version 1.0) to 87% (with ADA 2.0) for a set of 102 monoclonal antibodies, using JanusMatrix 2.0. Most of the improvement was for antibodies that had ADA that were higher than predicted using model 1.0. (FN near left axis, V 1.0, shifts to TP with V 2.0).
You are asking: Why? And how can I get my hands on this? The answers: This new version of the ADA prediction tool is informed by AI. The distinction between tolerogenic and immunogenic epitopes improved. And, the new ADA model will be integrated into our ISPRI toolkit soon! Come hear Guilhem speak about the new models at the AI/HI Seminar in June!
We’re Hitting the Road
Get the suitcases ready!
The Epi-team is heading out. Please check the events below and make a note – there are parties at every stop!
Providence is beautiful in June…
⭐EpiVax’s AI / HI & Immunoinformatics Workshop: June 5-6, Artificial Intelligence / Human Intelligence returns to Providence. This free event brings together scientists using AI and ML to tackle big questions in vaccine and drug development. Experts from Brown, Notre Dame, Bristol Myers Squibb, Harvard Med, will share their work. Seats are filling up fast!
Register online (it’s free!) and join the conversation on where AI is taking translational medicine next.
And more fun for the month of June…
⭐BIO International: June 16-19, Boston. Find us in the Rhode Island Pavillion or book a meeting with us…
But more importantly: let us know if you want to join the ⭐Epi-party⭐ on Tuesday night!
Speaking of amazing – join us to celebrate 30 years with Shimon Sakaguchi!
⭐Tregs as Medicine Workshop: Sept. 25, Tokyo, Japan
Bringing together leading scientists and researchers to examine how regulatory T cells (Tregs) and tolerance mechanisms can shape the future of biologics and vaccines.
Also in Tokyo…
⭐17th Westin Immunogenicity Seminar: Sept. 26, Tokyo, Japan
Join us as we exchange ideas about immunogenicity of AAV-delivered monoclonals, CAR-T, Multi-specifics, TCE!. We’ll have speakers from Janssen and BMS! This is a great forum for exchanging solutions.
And then there’s Amsterdam!
⭐The Amsterdam Immunogenicity & Tolerance Seminar: Nov. 7, Amsterdam, NL – More to follow!
Thanks for reading the Thinking Out Loud Newsletter! Want to receive it in your inbox every month?
And while we have your attention, we encourage you to Stand Up and Speak Out!
We can change the course of history!
– Annie
